Constitutively active ALK2 receptor mutants require type II receptor cooperation. by Bagarova, J, Vonner, A, Armstrong, K, Börgermann, J, Lai, C, Deng, D, Beppu, H, Alfano, I, Filippakopoulos, P, Morrell, N, Bullock, A, Knaus, P, Mishina, Y, Yu, P

Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva by Williams, E, Bagarova, J, Kerr, G, Xia, D-D, Place, ES, Dey, D, Shen, Y, Bocobo, GA, Mohedas, AH, Huang, X, Sanderson, PE, Lee, A, Zheng, W, Economides, AN, Smith, JC, Yu, PB, Bullock, AN